Jones Lang LaSalle Inc vs Twist Bioscience Corp — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.95B), while Twist Bioscience Corp trades at $155.24 (market cap $10.08B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Twist Bioscience Corp for 27 Days on average.
| JLL | TWST | |
|---|---|---|
Market Cap | $13.95B | $10.08B |
Volume | 457,462 | 4,229,037 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $205.00 |
52-Week Low | $280.16 | $25.45 |
Typical Hold Time | 71 Days | 27 Days |
Enterprise Value | $16.71B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% over 24 hours, with a bearish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a P/E of 14.54, P/S of 0.53, and net income margin of 3.64%. Recent earnings have consistently beaten expectations, and cash flow from operations reached $1.19 billion in 2025. Analyst consensus is bullish with a $450.50 price target, supported by positive news on acquisitions and growth prospects.
The outlook for JLL is positive due to robust earnings growth, improving profit margins, and strategic acquisitions. Risks include market volatility, competitive pressures in real estate services, and economic sensitivity. Institutional sentiment remains strong, with a majority of analysts recommending buy. The stock presents a value opportunity if it can sustain its operational momentum amid broader market headwinds.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →